Previous 10 | Next 10 |
home / stock / evtcy / evtcy news
HAMBURG, GERMANY / ACCESSWIRE / March 21, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN: DE0005664809)(NASDAQ:EVO) will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023. The Company is going to hold a conference call to discuss the results as ...
KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERS PERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$ 75 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / March 16, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE00056...
FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU) FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017 UNSECURED LOAN FACILITY TAILORED TO STRATEGIC PLAN...
EVOTEC AND RELATED SCIENCES COLLABORATE BY COMBINING COMPLEMENTARY CAPABILITIES TO ADVANCE PORTFOLIOS OF TRANSFORMATIONAL NEW MEDICINES THE PARTNERSHIP OVERSEES A GROWING PORTFOLIO OF MORE THAN 15 MULTI-MODALITY DRUG DISCOVERY PROGRAMMES EXTENSION AND EXPANSION THROUGH 2030 TO INCLUDE E...
HAMBURG, GERMANY / ACCESSWIRE / February 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective...
STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered in...
THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB HAMBURG, GERMANY / ACCESSWIRE / December 16, 2022 / Evotec SE (Frankfurt Stock Exchange: E...
MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY COMMERCIAL LAUNCH OF NEXT-GENERATION MULTI-OMICS DATA ANALYSIS PLATFORM PANHUNTER HAMBURG, GERMANY / ACCESSWIRE / November 9, 2022 / Evotec SE (Frankfurt Stock Exc...
AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC'S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt St...
TOGETHER FOR MEDICINES THAT MATTER: A PARADIGM SHIFT TO UNLOCK NEW MARKETS AND OPPORTUNITIES FOR GLOBAL ACCESS TO BIOLOGICS BY APPLYING A FULLY INTEGRATED, END-TO-END CONTINUOUS BIOMANUFACTURING PROCESS JUST - EVOTEC BIOLOGICS SELECTED FOR A SECOND AWARD UNDER THE US DEPARTMENT OF DEFE...
News, Short Squeeze, Breakout and More Instantly...
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D&...
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was un...
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS ...